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 Introduction 
 Contrast-induced nephropathy (CIN) is the third lead-
ing cause of hospital-acquired acute renal failure, con-
tributing not only to increased morbidity and mortality 
during hospitalization, but also to higher overall costs of 
health care  [1–6] . The risk factors for CIN are related to 
patient characteristics, ranging from the severity of the 
underlying renal disease and cardiovascular perfor-
mance, to the characteristics of the procedure itself, and 
to the quantity of contrast agent administered. Unfortu-
nately, despite being a major concern, the most effective 
strategy for the prevention of CIN is unknown.
 Although numerous preventive strategies involving 
the administration of furosemide, mannitol, dopamine, 
fenoldopam, atrial natriuretic peptide, and prostaglan-
din E 1 have been examined in randomized clinical trials, 
none have been found to be totally effective  [7–12] . Like-
wise, results for acetylcysteine, theophylline, and capto-
pril have been controversial  [13–18] . Despite ongoing 
studies to establish the value of pharmacologic preven-
tion, at present only volume supplementation is uniform-
ly accepted and used in clinical practice  [19–23] . Unfor-
tunately, little has yet been reported on the most effec-
tive approach to volume supplementation. In particular, 
details such as the timing and rate of infusion and the 
respective value of intravenous and oral volume supple-
mentation are not well defined. A combination of intra-
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 Abstract 
 Objective: The present study was performed to determine 
the effect of combined intravenous and oral volume supple-
mentation on the incidence of contrast-induced nephrop-
athy (CIN) in patients undergoing percutaneous coronary 
intervention (PCI).  Subjects and Methods: Consecutive pa-
tients (n = 958) receiving iomeprol 350 during PCI were eval-
uated prospectively for the development of CIN. All patients 
received protocol-defined intravenous and oral volume sup-
plementation. CIN was defined as an increase in serum cre-
atinine of at least 44   mol/l within 48 h.  Results: Of the 958 
patients enrolled in the study, 147 (15%) were diabetic and 
107 (11%) had stage III renal disease. The average baseline 
glomerular filtration rate was 88  8 25 ml/min/1.73 m 2 . Dur-
ing the intervention an average of 238  8 86 ml of contrast 
medium was administered. CIN developed in 13 of 958 (1.4%; 
95% confidence interval 0.6–2.1%) patients. The incidence of 
CIN was low even in predefined risk subgroups (women: 
2.4%, diabetics: 2.7%, patients with stage III kidney disease: 
6.5%).  Conclusions: The incidence of CIN is low when pre-
procedural fluid volume supplementation is used. 
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venous and oral volume supplementation has not gener-
ally been used in published studies.
 The present study was performed to determine the 
value of combined intravenous and oral volume supple-
mentation on the incidence of CIN in patients undergo-
ing percutaneous coronary intervention (PCI).
 Methods 
 Patients 
 Consecutive patients scheduled for elective or emergency PCI 
were enrolled in a prospective cohort study. Two different intra-
venous infusions schemes were used during the observational pe-
riod  [21] . Patients with end-stage renal failure on regular hemo-
dialysis or with cardiogenic shock and mechanical ventilation 
were excluded. Similarly, patients with coronary artery bypass 
grafting or who were undergoing repeat catheterization within
48 h of PCI were excluded from analysis.
 All patients received iomeprol 350 (Imeron, Bracco Altana 
Pharma, Germany), a low-osmolar, monomeric, nonionic con-
trast agent. PCI was performed via the femoral artery in all pa-
tients using a standard technique.
 For intravenous volume supplementation, roughly half of the 
patients (n = 494) received physiologic saline (0.9%; isotonic) 
while the remainder (n = 464) received 0.45% saline plus 5% glu-
cose (half-isotonic). Infusion was performed at a rate of 1 ml/kg 
of body weight per hour beginning at 8 a.m. on the day of PCI. In 
addition, patients were encouraged to drink plenty of fluids (tea, 
mineral water). Tea was provided to all patients in their room 
prior to the PCI procedure (500 ml) and in the post-PCI unit fol-
lowing the procedure (1,000 ml). In patients undergoing emer-
gency PCI, an infusion of 500 ml of crystalloid (Ringer’s) solution 
was initiated by the paramedics as their standard medical care 
before admission to the hospital. In this patient subset, isotonic 
and half-isotonic infusions were started immediately upon arriv-
al at the catheter laboratory. During PCI, the rate of infusion was 
adjusted to the clinical condition of the patient. After the proce-
dure, volume supplementation was continued at 1 ml/kg of body 
weight per hour until the following morning (8 a.m.).
 Follow-Up and Endpoints 
 Venous blood specimens were drawn on the morning before 
the PCI procedure, and at 24 and 48 h after the procedure for de-
termination of the serum creatinine level. All samples were ana-
lyzed in a central laboratory using a dedicated enzymatic kit 
(CREA plus, Boehringer Mannheim Systems, Mannheim, Ger-
many).
 Glomerular filtration rate (GFR) was calculated for all patients 
on the basis of creatinine clearance using the abbreviated ‘Modi-
fication of Diet in Renal Disease Study’ equation  [24–26] in which: 
GFR (in ml/min/1.73 m 2 of body surface area) = 186  ! (serum 
creatinine in mg/dl) –1.154  ! (age in years) –0.203  ! 0.742 in female 
subjects  ! 1.210 in black subjects.
 The most common definition of CIN, i.e., an increase in serum 
creatinine of at least 44   mol/l (0.5 mg/dl) within 48 h, was used 
as the primary endpoint in this trial.
 Statistical Analysis 
 Patients were evaluated primarily for the occurrence of CIN. 
Statistical analyses were performed using the SPSS/PC (version 
13, SPSS Inc., Chicago, Ill., USA) software package. Discrete vari-
ables were expressed as counts, and continuous variables as means 
 8 standard deviation (SD). Comparisons were made as appropri-
ate using Student’s t test for independent samples, the   2 -test, and 
Fisher’s exact test. All hypothesis testing was two-tailed at a sig-
nificance level of p  ! 0.05.
 Results 
 A total of 958 consecutive patients (mean age: 64  8 11 
years) were evaluated. A summary of patient and proce-
dural characteristics is given in  table 1 . The volume of 
administered contrast agent was similar for all patients 
irrespective of the presence of stage II or stage III kidney 
disease ( table 2 ). Approximately one third (n = 321) of the 
patient cohort was aged 70 years or older. Twenty-six per-
cent of patients were women and 15% were diabetic. A 
total of 462/958 (48%) patients had a prior history of myo-
cardial infarction and 71/958 (7%) underwent PCI for an 
acute ST-elevation myocardial infarction. Emergency in-
terventions accounted for slightly more than 50% of all 
procedures. Almost 50% of coronary lesions were com-
plex (lesion type B2 or C). A mean total volume of 238  8 
86 ml of iomeprol 350 was administered. None of the pa-
tients in this study received acetylcysteine or theophyl-
Table 1. Baseline clinical characteristics
Baseline characteristics Patients (n = 958)
n %
Aged ≥70 years 321 34
Female sex 247 26
Diabetes mellitus 147 15
Smoking 298 31
Arterial hypertension 612 64
Previous myocardial infarction 462 48
Acute myocardial infarction 71 7
Emergency procedures 550 57
Number of diseased vessels
1 346 36
2 273 29
3 339 35
Left ventricular ejection fraction (EF)
EF ≥ 60% 422 44
45% ≤ EF < 60% 389 41
30% ≤ EF < 45% 124 13
EF < 30% 23 2
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line and no changes in medication were allowed during 
the study period.
 The mean baseline renal function as assessed by cal-
culating GFR was 88  8 25 ml/min/1.73 m 2 . Stage II kid-
ney disease (GFR 60–90 ml/min/1.73 m 2 ) was present in 
412 patients (43%), while stage III kidney disease (GFR 
below 60 ml/min/1.73 m 2 ) was present in 107 (11%) pa-
tients ( table 2 ).
 Overall, CIN developed in 13 (1.4%; 95% confidence 
interval 0.6–2.1%) of the 958 patients evaluated ( table 3 ). 
The incidence of CIN was significantly higher in patients 
aged 70 years or older compared with patients younger 
than 70 years of age (2.5 vs. 0.8%, p = 0.040;  fig. 1 ). We 
observed no statistical difference between the occurrence 
of CIN in the isotonic and half-isotonic hydration groups 
(1.0 vs. 1.7%). A low incidence of CIN was observed even 
in established predefined risk subgroups including wom-
en (2.4%), diabetics (2.7%), and patients with stage III 
kidney disease (6.5%).
 Overall, 2 patients (0.2%) received dialysis during the 
hospitalization period. Neither of the events was a direct 
consequence of CIN, although both events were related 
to the PCI procedure. One 70-year-old female patient 
with mild chronic renal insufficiency and mitral regur-
gitation developed pulmonary edema during coronary 
angioplasty that required treatment with dialysis. The 
other patient, a 77-year-old male with severe chronic re-
nal insufficiency, had already undergone a shunt opera-
tion in the preceding week and was scheduled to begin 
chronic dialysis in 4 weeks. The operator elected to leave 
the arterial sheath in place for acute dialysis after coro-
nary angiography and PCI had been performed. During 
the follow-up period no additional patients required sub-
sequent chronic dialysis.
 Discussion 
 The results of the large prospective cohort study con-
firm that the combined use of intravenous and oral vol-
ume supplementation results in a very low incidence of 
CIN. The overall incidence of CIN in this cohort was only 
1.4%. This is considerably lower than values reported pre-
viously in similar patient populations  [1–20] . For exam-
ple, an incidence of 3.3% has recently been reported in a 
retrospective analysis of the Mayo Clinic PCI registry  [6] . 
Particularly noteworthy in the present study was an over-
all incidence of CIN of only 6.5% in patients with stage 
III kidney disease (a GFR below 60 ml/min/1.73m2). The 
results presented herein support previously published re-
Table 2. Subgroup details
All patients
(n = 958)
≤ Stage I kidney disease
(n = 439)
Stage II kidney disease
(n = 412)
Stage III kidney
disease (n = 107)
isotonic half-isotonic isotonic half-isotonic isotonic half-isotonic isotonic half-isotonic
Isotonicity of saline 494 (52%) 464 (48%) 228 (52%) 211 (48%) 213 (52%) 199 (48%) 53 (50%) 54 (50%)
Contrast dose, ml 235881 240891 235874 235889 239889 247896 221872 236882
Serum creatinine, mol/l
Baseline 82827 82825 66810 66810 86812 86812 133846 129835
24 h 80826 81827 68811 68814 82815 82815 122851 126846
48 h 89834 88826 74811 73812 90819 90817 141869 133837
Table 3. Incidence of CIN in patients (n = 958) undergoing PCI
Patients 95% CI
Overall CIN 13 (1.4) 0.6–2.1
CIN subgroups
Men (n = 711) 7 (1.0) 0.3–1.7
Women (n = 247) 6 (2.4) 0.5–4.4
Age <70 years (n = 637) 5 (0.8) 0–1.5
CIN Age ≥70 years (n = 321) 8 (2.5) 0.8–4.2
Nondiabetics (n = 811) 9 (1.1) 0.4–1.8
Diabetics (n = 147) 4 (2.7) 0.1–5.1
GFR ≥60 ml/min/1.73 m2
(n = 851) 6 (0.7) 0.1–1.3
GFR <60 ml/min/1.73 m2
(n = 107) 7 (6.5) 1.8–11.3
CIN was defined as an increase in serum creatinine of at least 
44 mol/l within 48 h. Number and percent (in parentheses) of 
patients are given. CI = Confidence interval.
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sults  [22] and suggest that the combined use of intrave-
nous and oral volume supplementation provides a safe, 
simple, effective, and inexpensive strategy for the preven-
tion of CIN. Furthermore, our data confirm the findings 
of recent studies suggesting that age is a major risk factor 
for CIN  [16, 27] .
 Approximately 30 years ago it was documented that 
hypovolemia accentuates the risk of CIN  [28] . The inci-
dence was higher in summer and when patients were pre-
vented from drinking before excretory urograms in order 
to maximize the concentration of contrast medium in the 
urinary tract. Observations comparing hydrated patients 
with historical controls first provided evidence that a flu-
id load might prevent CIN  [27, 29–31] . In 1994, these data 
were supported by a controlled study, primarily under-
taken to investigate the value of mannitol and furosemide 
administration  [7] . In a randomized controlled study of 
78 patients with mild to moderate renal insufficiency, sa-
line administration (0.45% saline over 24 h starting 12 h 
before administration of contrast medium) alone was 
more effective than the combination of volume supple-
mentation with mannitol or furosemide  [7] . Recently, 
three randomized studies have specifically examined the 
effectiveness of intravenous volume supplementation  [22, 
23, 32] . Trivedi et al.  [22] randomized 53 patients on the 
day prior to scheduled elective cardiac catheterization to 
one of two groups: group 1 (n = 27) received normal sa-
line for 24 h (at a rate of 1 ml/kg/h) beginning 12 h prior 
to scheduled catheterization, while the patients of group 
2 (n = 26) were allowed unrestricted oral fluids. The in-
cidence of acute renal failure was significantly lower in 
group 1 (1 out of 27; 3.7%) than in group 2 (9 out of 26, 
34.6%; p = 0.005 for comparison between groups; relative 
risk 0.11, 95% confidence interval 0.02–0.79). Bader et al. 
 [23] randomized 39 patients with normal renal function, 
who were due to undergo an angiographic procedure 
with at least 80 ml of low osmolar contrast medium, to 
one of two volume supplementation regimens: group 1, 
volume expansion with 300 ml saline during contrast 
medium administration (n = 20); group 2, intravenous 
administration of at least 2,000 ml saline within 12 h be-
fore and after contrast medium application (n = 19). Pa-
tients in group 1 showed a significantly higher decline in 
GFR (  GFR = 35 ml/min/1.73 m 2 ) compared to patients 
in group 2, who received the intravenous prehydration 
regimen (  GFR = 18 ml/min/1.73 m 2 ; p  ! 0.05). In the 
third study, Krasuski et al.  [32] randomized 63 patients 
with moderate renal insufficiency who were scheduled 
for elective cardiac catheterization to two groups to re-
ceive either overnight hydration (n = 26) with intrave-
nous 5% dextrose in 0.45% saline (infused at 1 ml/kg/h 
beginning at least 12 h before the procedure) or bolus hy-
dration (n = 37) at the time of the procedure (250 ml of 
0.9% saline administered over 20 min). After the proce-
dure all patients were encouraged to take in oral fluids 
and received intravenous 5% dextrose in 0.45% saline at 
1 ml/kg/h for 12 h. Although no overall change in serum 
creatinine was seen at 24 or 48 h after the procedure, 4 
out of 37 (10.8%) patients who received bolus hydration 
developed CIN compared with 0 out of 26 (0.0%) patients 
who received overnight hydration.
 It is important to note that volume expansion per-
formed only during exposure to the contrast agent ap-
pears insufficient in itself to prevent renal damage  [23, 
32] . Whether the use of sodium bicarbonate allows short-
er infusion periods has to be examined in future studies 
 [33] .
 This study has several limitations. First, as with all su-
prarenal procedures performed via the femoral artery, it 
is unclear to what extent atheroembolism into the renal 
arteries induced by catheter manipulation during cathe-
terization contributed to the decline in renal function. 
Therefore, the renal damage attributable to iomeprol may 
be even lower than reported in this study. Second, half-
isotonic rather than isotonic hydration was used in 48% 
of patients in the study. Because isotonic hydration is su-
perior to half-isotonic hydration  [21] , again it is likely that 
an even lower incidence of CIN would have been ob-
served had isotonic hydration been applied to all patients 
in this study. Third, comparison with historical controls 
invariably introduces bias due to potential differences in 
baseline characteristics. Additionally, this was a single-
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center study. Hence, further data from multicenter stud-
ies are required to further strengthen our findings.
 Although the pathogenesis of CIN is only incomplete-
ly understood, it seems to involve renal vasoconstriction, 
medullary hypoxia, increased red cell aggregation, and 
direct toxic effects on renal epithelial cells  [6, 17, 19] . Ac-
cordingly, plasma volume expansion combined with con-
comitant suppression of the renin-angiotensin-aldoste-
rone system, down-regulation of the tubuloglomerular 
feedback, dilution of the contrast agent with resulting 
prevention of renal cortical vasoconstriction, and avoid-
ance of tubular obstruction has enormous theoretical ap-
peal  [17, 19] . Unfortunately, poor control of all relevant 
variables including intravenous and oral volume supple-
mentation has led to widely conflicting data regarding 
the reported incidence of CIN and its risk factors  [27] . As 
demonstrated in this study, the combination of intrave-
nous and oral volume supplementation seems to be an 
attractive option for the vast majority of patients under-
going intravenous or intra-arterial contrast procedures. 
Given the fact that all alternative strategies have signifi-
cant limitations, it seems of paramount importance to 
highlight the effectiveness of stringent volume supple-
mentation as a baseline measure.
 Conclusion 
 The use of combined intravenous and oral volume 
supplementation results in a very low incidence of CIN 
following PCI with iomeprol 350 in patients at moderate 
risk. Volume supplementation should remain the corner-
stone for prevention of CIN.
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